Tempus AI, Inc. Class A Common Stock Q3 2025 Earnings Recap

TEM Q3 2025 November 5, 2025

Get alerts when TEM reports next quarter

Tempus AI reported a strong Q3 2025, achieving robust growth in both Genomics and Data Licensing, culminating in the company’s first positive adjusted EBITDA.

Earnings Per Share Beat

$-0.11 vs $-0.17 est.

+36.2% surprise

Revenue Beat

334206000 vs 328702869 est.

+1.7% surprise

Market Reaction

1-Day -2.64%

5-Day -15.04%

30-Day -7.49%

See TEM alongside your other holdings

Add to your portfolio — free

Key Takeaways

Genomics volume surged 33% overall, with notable growth in Hereditary (37%) and Oncology (27%).
The Data Licensing segment grew 38%, adding $150 million in total contract value.
Achieved positive adjusted EBITDA for the first time, a significant milestone after 10 years, despite expenses from the Paige acquisition.
Growth is underpinned by improved sales efficiency and advancements in their integrated technology offerings.
Adjusted EBITDA for the full year is now expected to be slightly positive, even accounting for additional costs from acquisitions.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TEM on AllInvestView.

Next Q1 2026